Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects.

Editorial study summary

Study type

Human randomized trial

Product relevance

NAD+ precursor and human biomarker context; not this 160 mg + 80 mg formula.

Sample or population

30 healthy adults; 15 NMN and 15 placebo

Studied dose

NMN 250 mg/day

Duration

12 weeks

Finding

Blood NAD+ increased with NMN supplementation; the monitored physiological and laboratory assessments did not identify obvious adverse effects over the study period.

Limitations

Small, short trial of NMN alone at a different dose. A blood biomarker increase does not establish longer life or broad clinical benefit, and short-term tolerability is not a universal safety guarantee.

Study quality

Full text and PubMed

Funding and disclosures

Funded by Mitsubishi Corporation Life Sciences; several authors were employees and supplied study material. Additional facility support is listed in the paper.

This research does not establish results for a DR.MORGAN finished product.

Reference

1. Okabe K et al. · 2022 · PMID 35479740